GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (STU:NG9) » Definitions » Cyclically Adjusted PB Ratio

NeoGenomics (STU:NG9) Cyclically Adjusted PB Ratio : 2.58 (As of Jun. 10, 2024)


View and export this data going back to 2016. Start your Free Trial

What is NeoGenomics Cyclically Adjusted PB Ratio?

As of today (2024-06-10), NeoGenomics's current share price is €11.80. NeoGenomics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €4.57. NeoGenomics's Cyclically Adjusted PB Ratio for today is 2.58.

The historical rank and industry rank for NeoGenomics's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:NG9' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.63   Med: 16.75   Max: 49.88
Current: 2.48

During the past years, NeoGenomics's highest Cyclically Adjusted PB Ratio was 49.88. The lowest was 1.63. And the median was 16.75.

STU:NG9's Cyclically Adjusted PB Ratio is ranked worse than
59.12% of 137 companies
in the Medical Diagnostics & Research industry
Industry Median: 2 vs STU:NG9: 2.48

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

NeoGenomics's adjusted book value per share data for the three months ended in Mar. 2024 was €6.666. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €4.57 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


NeoGenomics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for NeoGenomics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Cyclically Adjusted PB Ratio Chart

NeoGenomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.00 25.36 10.85 2.23 3.24

NeoGenomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.96 3.48 2.54 3.24 3.00

Competitive Comparison of NeoGenomics's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, NeoGenomics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeoGenomics's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Cyclically Adjusted PB Ratio falls into.



NeoGenomics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

NeoGenomics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=11.80/4.57
=2.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, NeoGenomics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=6.666/131.7762*131.7762
=6.666

Current CPI (Mar. 2024) = 131.7762.

NeoGenomics Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.340 100.560 0.446
201409 0.764 100.428 1.002
201412 0.813 99.070 1.081
201503 0.921 99.621 1.218
201506 0.896 100.684 1.173
201509 0.909 100.392 1.193
201512 2.537 99.792 3.350
201603 2.401 100.470 3.149
201606 2.327 101.688 3.016
201609 2.279 101.861 2.948
201612 1.975 101.863 2.555
201703 1.990 102.862 2.549
201706 1.895 103.349 2.416
201709 1.770 104.136 2.240
201712 1.806 104.011 2.288
201803 1.737 105.290 2.174
201806 1.722 106.317 2.134
201809 2.798 106.507 3.462
201812 2.982 105.998 3.707
201903 3.007 107.251 3.695
201906 4.174 108.070 5.090
201909 4.333 108.329 5.271
201912 4.358 108.420 5.297
202003 4.337 108.902 5.248
202006 5.262 108.767 6.375
202009 5.096 109.815 6.115
202012 5.092 109.897 6.106
202103 6.050 111.754 7.134
202106 7.767 114.631 8.929
202109 7.845 115.734 8.932
202112 7.903 117.630 8.853
202203 7.826 121.301 8.502
202206 7.855 125.017 8.280
202209 8.084 125.227 8.507
202212 7.423 125.222 7.812
202303 7.155 127.348 7.404
202306 6.941 128.729 7.105
202309 6.976 129.860 7.079
202312 6.779 129.419 6.902
202403 6.666 131.776 6.666

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NeoGenomics  (STU:NG9) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


NeoGenomics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoGenomics (STU:NG9) Business Description

Traded in Other Exchanges
Address
9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.

NeoGenomics (STU:NG9) Headlines

No Headlines